

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1.-51. (Cancelled)

52.-75. (Not entered)

76.-104. (Cancelled)

105. (Not entered)

106. (New) An isolated, non-tumorigenic cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

- (a) culturing embryonic stem cells to produce neural precursor cells;
- (b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;
- (c) culturing the cells from (b) in a second growth factor-containing serum-free medium; and
- (d) culturing the cells from (c) in a third growth factor-containing serum-free medium, to obtain the cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

wherein the embryonic stem cells are murine or human embryonic stem cells and are not human genetically modified embryonic stem cells.

107. (New) The cell composition according to claim 106, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

108. (New) The cell composition according to claim 106, wherein the cells of steps (c) and (d) grow as a monolayer.
109. (New) The cell composition according to claim 106, comprising cells with neuronal, astroglial or oligodendroglial properties.
110. (New) The cell composition according to claim 106, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.
111. (New) The cell composition according to claim 106, wherein the embryonic stem cells are obtained from embryonic germ cells.
112. (New) The cell composition of claim 106, wherein the embryonic stem cells in (a) are cultured in serum-free medium.
113. (New) The cell composition of claim 107, wherein the cell aggregates are embryoid bodies.
114. (New) A cell library comprising cells according to claim 106, which are autologous and nonautologous cells.
115. (New) A pharmaceutical composition comprising the precursor cells of claim 106.
116. (New) The cell composition according to claim 106, wherein the second growth factor-containing serum-free medium comprises bFGF and EGF.
117. (New) The cell composition according to claim 106, wherein the third growth factor-containing serum-free medium comprises bFGF and PDGF.

118. (New) An isolated, non-tumorigenic cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

- (a) culturing embryonic stem cells to produce neural precursor cells;
- (b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium; and
- (c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells,

wherein the embryonic stem cells are murine or human embryonic stem cells and are not human genetically modified embryonic stem cells.

119. (New) The cell composition according to claim 118, wherein the embryonic stem cells in (a) are in the form of cell aggregates.

120. (New) The cell composition of claim 119, wherein the cell aggregates are embryoid bodies.

121. (New) The cell composition of claim 118, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

122. (New) The cell composition according to claim 118, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

123. (New) The cell composition according to claim 118, wherein the embryonic stem cells are obtained from embryonic germ cells.

124. (New) A cell library comprising cells according to claim 118, which are autologous and nonautologous cells.
125. (New) A pharmaceutical composition comprising the precursor cells of claim 118.
126. (New) The cell composition according to claim 118, wherein the second growth factor-containing serum-free medium comprises bFGF and EGF.
127. (New) An isolated, non-tumorigenic cell composition consisting essentially of embryonic stem cell-derived glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells,

the composition being obtainable by:

- (a) culturing embryonic stem cells to produce neural precursor cells;
- (b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;
- (c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres; and
- (d) culturing the neural spheres from (c) in a third growth factor-containing serum-free medium to produce a monolayer of glial precursor cells, and glial cells derived from the embryonic stem cell-derived glial precursor cells,

wherein the embryonic stem cells are murine or human embryonic stem cells and are not human genetically modified embryonic stem cells.

128. (New) The cell composition according to claim 126, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.
129. (New) The cell composition of claim 128, wherein the cell aggregates are embryoid bodies.

130. (New) The cell composition of claim 126, wherein the embryonic stem cells in (a) are cultured in serum-free medium.
131. (New) The cell composition according to claim 126, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.
132. (New) The cell composition according to claim 126, wherein the embryonic stem cells are obtained from embryonic germ cells.
133. (New) A cell library comprising cells according to claim 126, which are autologous and nonautologous cells.
134. (New) A pharmaceutical composition comprising the precursor cells of claim 126.
135. (New) The cell composition according to claim 126, wherein the second growth factor-containing serum-free medium comprises bFGF and EGF.
136. (New) The cell composition according to claim 126, wherein the third growth factor-containing serum-free medium comprises bFGF, EGF, or a combination thereof.